A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer

. 2010 Nov-Dec;28(6):655-61.

doi: 10.1016/j.urolonc.2009.01.027. Epub 2009 Apr 17.

Affiliations

PMID: 19375957
DOI: 10.1016/j.urolonc.2009.01.027

Merle Hanke et al. Urol Oncol. 2010 Nov-Dec.

Abstract

Objectives: MicroRNAs have been shown to be related to specific types of malignant cell growth. In case of urothelial bladder cancer (BCa), novel noninvasive diagnosis is particularly required and it is attractive to consider, as urine is an easily available source for molecular markers including RNA. In this context, we aimed to develop a clinically applicable and sensitive protocol for the preparation and molecular analysis of low molecular weight RNA from urine samples obtained from bladder cancer patients or healthy volunteers.

Materials and methods: First, a method was developed for the preparation of low molecular weight RNA from a set of urine samples from different donor groups: (1) patients with low-grade BCa, (2) patients with high-grade BCa, (3) patients with urinary tract infections, (4) healthy donors; each n = 9. The RNA extracts were then used to monitor a number of 157 microRNA species by quantitative reverse transcriptase-polymerase chain reaction. Subsequently, those microRNAs that showed a higher abundance in urine samples from BCa patients were detected in an independent set of urine samples (n = 47).

Results: The significance and diagnostic usefulness of this methodology is reflected by the finding that the RNA ratio of microRNA-126:microRNA-152 enabled the detection of BCa from urine at a specificity of 82% and a sensitivity of 72%, with an area under the curve of 0.768 (95% confidence interval, 0.605-0.931).

Conclusions: This study describes a novel, robust, and useful technology platform that is suitable to analyze small RNAs, including novel RNA-based tumor markers, in urine samples. A detailed technical analysis of this methodology provides new insights into the characteristics of urine microRNA such as composition and the donor-dependent variability.

PubMed Disclaimer

Cited by

From small to big: microRNAs as new players in medulloblastomas.
Zhi F, Wang S, Wang R, Xia X, Yang Y. Zhi F, et al. Tumour Biol. 2013 Feb;34(1):9-15. doi: 10.1007/s13277-012-0579-9. Epub 2012 Nov 25. Tumour Biol. 2013. PMID: 23179395 Review.
MICROFLUIDIC DEVICES FOR LABEL-FREE AND NON-INSTRUMENTED QUANTITATION OF UNAMPLIFIED NUCLEIC ACIDS BY FLOW DISTANCE MEASUREMENT.
Chatterjee D, Mansfield DS, Woolley AT. Chatterjee D, et al. Anal Methods. 2014 Oct 21;6(20):8173-8179. doi: 10.1039/C4AY01845A. Anal Methods. 2014. PMID: 25530814 Free PMC article.
miRNA - Therapeutic tool in breast cancer? Where are we now?
Zaleska K. Zaleska K. Rep Pract Oncol Radiother. 2014 Nov 26;20(2):79-86. doi: 10.1016/j.rpor.2014.10.009. eCollection 2015 Mar-Apr. Rep Pract Oncol Radiother. 2014. PMID: 25859396 Free PMC article. Review.
Circulating miRNAs and Preeclampsia: From Implantation to Epigenetics.
Giannubilo SR, Cecati M, Marzioni D, Ciavattini A. Giannubilo SR, et al. Int J Mol Sci. 2024 Jan 24;25(3):1418. doi: 10.3390/ijms25031418. Int J Mol Sci. 2024. PMID: 38338700 Free PMC article. Review.
Identification of miR-29c-3p as a Robust Normalizer for Urine microRNA Studies in Bladder Cancer.
Oto J, Plana E, Fernández-Pardo Á, Cana F, Martínez-Sarmiento M, Vera-Donoso CD, España F, Medina P. Oto J, et al. Biomedicines. 2020 Oct 22;8(11):447. doi: 10.3390/biomedicines8110447. Biomedicines. 2020. PMID: 33105660 Free PMC article.

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer - PubMed (original) (raw)